Journal List > Korean J Gastroenterol > v.60(6) > 1007028

See the article "".
Jung: What Is the Effect of Metformin Combined to Chemotherapy in Stage IV Colorectal Cancer with Diabetes?

Notes

Financial support: None.

Conflict of interest: None.

References

1. National Cancer Information Center [Internet]. Goyang (Korea): National Cancer Information Center;Available from: http://www.cancer.go.kr.
2. Schoen RE, Tangen CM, Kuller LH, et al. Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst. 1999. 91:1147–1154.
3. Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005. 17:596–603.
4. Hosono K, Endo H, Takahashi H, et al. Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by activating AMP-activated protein kinase. Mol Carcinog. 2010. 49:662–671.
5. Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012. 7:e33411.
6. Lee JH, Kim TI, Jeon SM, Hong SP, Cheon JH, Kim WH. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 2012. 131:752–759.
7. Tseng CH. Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. Eur J Endocrinol. 2012. 167:409–416.
8. Lee DJ, Kim B, Lee JH, et al. The Effect of metformin on the response to chemotherapy and survival in stage IV colorectal cancer with diabetes. Korean J Gastroenterol. 2012. 60:355–361.
9. Higurashi T, Takahashi H, Endo H, et al. Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial. BMC Cancer. 2012. 12:118.
TOOLS
Similar articles